Description

LETROVAC 2.5 MG

Indications

LETROVAC 2.5 MG is primarily indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is particularly effective in patients who have undergone surgery and are receiving adjuvant therapy to reduce the risk of cancer recurrence. LETROVAC is also used in the treatment of advanced breast cancer in postmenopausal women when the disease has progressed following anti-estrogen therapy.

Mechanism of Action

LETROVAC contains letrozole, an aromatase inhibitor that works by inhibiting the aromatase enzyme, which is responsible for the conversion of androgens to estrogens in peripheral tissues. By reducing estrogen levels in the body, LETROVAC helps to slow or stop the growth of hormone-sensitive tumors, particularly in breast cancer. This mechanism is crucial as many breast cancers rely on estrogen to grow and proliferate.

Pharmacological Properties

LETROVAC is characterized by its high specificity for the aromatase enzyme, leading to a significant reduction in circulating estrogen levels. The pharmacokinetics of letrozole indicate that it is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 1 to 2 hours post-dose. The drug has a half-life of about 2 days, allowing for once-daily dosing. LETROVAC is primarily metabolized in the liver and excreted through urine, with minimal excretion of unchanged drug.

Contraindications

LETROVAC should not be used in patients with known hypersensitivity to letrozole or any of its components. It is also contraindicated in premenopausal women, as its efficacy and safety have not been established in this population. Additionally, patients with severe liver impairment should avoid using LETROVAC due to the potential for increased drug accumulation and adverse effects.

Side Effects

Common side effects associated with LETROVAC include hot flashes, joint pain, fatigue, and nausea. Other potential side effects may include headache, dizziness, and increased sweating. In some cases, patients may experience more serious side effects such as bone density loss, which can lead to osteoporosis and fractures. It is essential for patients to discuss any side effects experienced during treatment with their healthcare provider for appropriate management.

Dosage and Administration

The recommended dosage of LETROVAC is 2.5 mg taken orally once daily. It can be taken with or without food, and it is important for patients to adhere to the prescribed dosage regimen to maximize therapeutic benefits. Treatment duration may vary based on individual patient factors and the clinical judgment of the healthcare provider. Regular monitoring of bone mineral density is recommended for patients on long-term LETROVAC therapy.

Interactions

LETROVAC may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. Notable interactions include those with other drugs that are metabolized by the liver, particularly CYP2A6 and CYP3A4 substrates. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions. Caution is advised when LETROVAC is used in conjunction with other cancer therapies or medications that may affect bone health.

Precautions

Before starting LETROVAC, patients should undergo a thorough evaluation to assess their overall health and any existing medical conditions. Special precautions should be taken in patients with a history of osteoporosis or fractures, as LETROVAC may exacerbate these conditions. Regular monitoring of bone density is recommended. Additionally, patients should be advised to report any unusual symptoms, such as persistent joint pain or signs of cardiovascular issues, to their healthcare provider promptly.

Clinical Studies

Clinical studies have demonstrated the efficacy of LETROVAC in the treatment of hormone receptor-positive breast cancer. In a pivotal trial, postmenopausal women with early-stage breast cancer who received LETROVAC showed a significant reduction in the risk of recurrence compared to those receiving placebo. Another study indicated that LETROVAC was effective in patients with advanced breast cancer, leading to improved progression-free survival rates. These studies underscore the importance of LETROVAC in the management of breast cancer in appropriate patient populations.

Conclusion

LETROVAC 2.5 MG is a vital therapeutic option for postmenopausal women with hormone receptor-positive breast cancer. Its mechanism of action as an aromatase inhibitor effectively reduces estrogen levels, thereby inhibiting tumor growth. While generally well-tolerated, patients should be aware of potential side effects and interactions with other medications. Ongoing monitoring and communication with healthcare providers are crucial for optimizing treatment outcomes and ensuring patient safety.